Posted by Michael Wonder on 02 Oct 2016

Biosimilars in inflammatory bowel disease

Medical Journal of Australia

3 October 2016 - Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited.

Read Medical Journal of Australia article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Australia , Market access , Biosimilar , Drug utilisation